Also, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), beyond their established metabolic effects in type 2 diabetes, may exert protective actions in patients with coexisting COPD. The gene discussed is GLP1R; the disease is chronic obstructive pulmonary disease.